{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-039300","form_type":"8-K","ticker":"MGRX","cik":"0001938046","company_name":"MANGOCEUTICALS, INC.","filed_at":"2024-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.386881+00:00","generated_at":"2026-05-30T21:45:35.439559+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MangoRx launches oral Tirzepatide weight loss tablet 'TRIM' at $399/month","bullets":["TRIM is a compounded oral dissolvable Tirzepatide tablet priced at $399 per month.","Tirzepatide is a dual GIP/GLP-1 receptor agonist; clinical trials showed up to 20% weight loss in 72 weeks.","TRIM complements existing oral Semaglutide product (SLIM), offering two GLP-1 options.","Global GLP-1 market projected to grow from $49.3B (2024) to $157.5B by 2035 per Roots Analysis.","Available by prescription via MangoRx telemedicine platform; targets non-injectable weight loss demand."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-039300","json":"https://secwatch.observer/filing/0001493152-24-039300.json","markdown":"https://secwatch.observer/filing/0001493152-24-039300.md","text":"https://secwatch.observer/filing/0001493152-24-039300.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938046/000149315224039300/0001493152-24-039300-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938046/000149315224039300/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T21:45:35.439559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}